Report cover image

G8 Countries Pharmaceuticals Market Summary, Competitive Analysis and Forecast, 2018-2027

Publisher MarketLine
Published Oct 25, 2023
Length 209 Pages
SKU # MTLN18362559

Description

G8 Countries Pharmaceuticals Market Summary, Competitive Analysis and Forecast, 2018-2027


Summary

The G8 Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2018-22, and forecast to 2027). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights
  • The G8 countries contributed $774.7 billion in 2022 to the global pharmaceuticals industry, with a compound annual growth rate (CAGR) of 2.3% between 2018 and 2022. The G8 countries are expected to reach a value of $897.4 billion in 2027, with a CAGR of 3% over the 2022-27 period.
  • Among the G8 nations, the US is the leading country in the pharmaceuticals industry, with market revenues of $408.0 billion in 2022. This was followed by Japan and Germany, with a value of $92.3 and $83.2 billion, respectively.
  • The US is expected to lead the pharmaceuticals industry in the G8 nations with a value of $463.0 billion in 2016, followed by Germany and Japan with expected values of $107.9 and $106.5 billion, respectively.
Scope
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the G8 pharmaceuticals market
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the G8 pharmaceuticals market
  • Leading company profiles reveal details of key pharmaceuticals market players’ G8 operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the G8 pharmaceuticals market with five year forecasts
  • Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country
Reasons to Buy
  • What was the size of the G8 pharmaceuticals market by value in 2022?
  • What will be the size of the G8 pharmaceuticals market in 2027?
  • What factors are affecting the strength of competition in the G8 pharmaceuticals market?
  • How has the market performed over the last five years?
  • Who are the top competitors in the G8 pharmaceuticals market?

Table of Contents

209 Pages
1 Introduction
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions
2 Group of Eight (G8) Pharmaceuticals
2.1. Industry Outlook
3 Pharmaceuticals in Canada
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
4 Macroeconomic Indicators
4.1. Country data
5 Pharmaceuticals in France
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
6 Macroeconomic Indicators
6.1. Country data
7 Pharmaceuticals in Germany
7.1. Market Overview
7.2. Market Data
7.3. Market Segmentation
7.4. Market outlook
7.5. Five forces analysis
8 Macroeconomic Indicators
8.1. Country data
9 Pharmaceuticals in Italy
9.1. Market Overview
9.2. Market Data
9.3. Market Segmentation
9.4. Market outlook
9.5. Five forces analysis
10 Macroeconomic Indicators
10.1. Country data
11 Pharmaceuticals in Japan
11.1. Market Overview
11.2. Market Data
11.3. Market Segmentation
11.4. Market outlook
11.5. Five forces analysis
12 Macroeconomic Indicators
12.1. Country data
13 Pharmaceuticals in Russia
13.1. Market Overview
13.2. Market Data
13.3. Market Segmentation
13.4. Market outlook
13.5. Five forces analysis
14 Macroeconomic Indicators
14.1. Country data
15 Pharmaceuticals in The United Kingdom
15.1. Market Overview
15.2. Market Data
15.3. Market Segmentation
15.4. Market outlook
15.5. Five forces analysis
16 Macroeconomic Indicators
16.1. Country data
17 Pharmaceuticals in The United States
17.1. Market Overview
17.2. Market Data
17.3. Market Segmentation
17.4. Market outlook
17.5. Five forces analysis
18 Macroeconomic Indicators
18.1. Country data
19 Company Profiles
19.1. Johnson & Johnson
19.2. Apotex, Inc.
19.3. Laboratoires Pierre Fabre SA
19.4. F. Hoffmann-La Roche Ltd
19.5. Boehringer Ingelheim GmbH
19.6. A Menarini Industrie Farmaceutiche Riunite Srl
19.7. Recordati S.p.A.
19.8. Chiesi Farmaceutici SpA
19.9. Daiichi Sankyo Co Ltd
19.10. Astellas Pharma Inc.
19.11. Takeda Pharmaceutical Company Limited
19.12. Mitsubishi Tanabe Pharma Corporation
19.13. Sanofi SA
19.14. Bayer AG
19.15. Les Laboratoires Servier
19.16. Novartis AG
19.17. GSK plc.
19.18. Merck & Co., Inc.
19.19. Pfizer Inc.
19.20. AstraZeneca PLC
20 Appendix
20.1. Methodology
20.2. About MarketLine
List of Tables
Table 1: G8 pharmaceuticals industry, revenue($bn), 2018-27
Table 2: G8 pharmaceuticals industry, revenue by country ($bn), 2018-22
Table 3: G8 pharmaceuticals industry forecast, revenue by country ($bn), 2022-27
Table 4: Canada pharmaceuticals market value: $ billion, 2017-22
Table 5: Canada pharmaceuticals market geography segmentation: $ billion, 2022
Table 6: Canada pharmaceuticals market value forecast: $ billion, 2022–27
Table 7: Canada size of population (million), 2018–22
Table 8: Canada gdp (constant 2005 prices, $ billion), 2018–22
Table 9: Canada gdp (current prices, $ billion), 2018–22
Table 10: Canada inflation, 2018–22
Table 11: Canada consumer price index (absolute), 2018–22
Table 12: Canada exchange rate, 2018–22
Table 13: France pharmaceuticals market value: $ billion, 2017-22
Table 14: France pharmaceuticals market geography segmentation: $ billion, 2022
Table 15: France pharmaceuticals market value forecast: $ billion, 2022–27
Table 16: France size of population (million), 2018–22
Table 17: France gdp (constant 2005 prices, $ billion), 2018–22
Table 18: France gdp (current prices, $ billion), 2018–22
Table 19: France inflation, 2018–22
Table 20: France consumer price index (absolute), 2018–22
Table 21: France exchange rate, 2018–22
Table 22: Germany pharmaceuticals market value: $ billion, 2017-22
Table 23: Germany pharmaceuticals market geography segmentation: $ billion, 2022
Table 24: Germany pharmaceuticals market value forecast: $ billion, 2022–27
Table 25: Germany size of population (million), 2018–22
Table 26: Germany gdp (constant 2005 prices, $ billion), 2018–22
Table 27: Germany gdp (current prices, $ billion), 2018–22
Table 28: Germany inflation, 2018–22
Table 29: Germany consumer price index (absolute), 2018–22
Table 30: Germany exchange rate, 2018–22
Table 31: Italy pharmaceuticals market value: $ billion, 2017-22
Table 32: Italy pharmaceuticals market geography segmentation: $ billion, 2022
Table 33: Italy pharmaceuticals market value forecast: $ billion, 2022–27
Table 34: Italy size of population (million), 2018–22
Table 35: Italy gdp (constant 2005 prices, $ billion), 2018–22
Table 36: Italy gdp (current prices, $ billion), 2018–22
Table 37: Italy inflation, 2018–22
Table 38: Italy consumer price index (absolute), 2018–22
Table 39: Italy exchange rate, 2018–22
Table 40: Japan pharmaceuticals market value: $ billion, 2017-22
Table 41: Japan pharmaceuticals market geography segmentation: $ billion, 2022
Table 42: Japan pharmaceuticals market value forecast: $ billion, 2022–27
Table 43: Japan size of population (million), 2018–22
Table 44: Japan gdp (constant 2005 prices, $ billion), 2018–22
Table 45: Japan gdp (current prices, $ billion), 2018–22
Table 46: Japan inflation, 2018–22
Table 47: Japan consumer price index (absolute), 2018–22
Table 48: Japan exchange rate, 2018–22
Table 49: Russia pharmaceuticals market value: $ billion, 2017-22
Table 50: Russia pharmaceuticals market geography segmentation: $ billion, 2022
Table 51: Russia pharmaceuticals market value forecast: $ billion, 2022–27
Table 52: Russia size of population (million), 2018–22
Table 53: Russia gdp (constant 2005 prices, $ billion), 2018–22
Table 54: Russia gdp (current prices, $ billion), 2018–22
Table 55: Russia inflation, 2018–22
Table 56: Russia consumer price index (absolute), 2018–22
Table 57: Russia exchange rate, 2018–22
Table 58: United Kingdom pharmaceuticals market value: $ billion, 2017-22
Table 59: United Kingdom pharmaceuticals market geography segmentation: $ billion, 2022
Table 60: United Kingdom pharmaceuticals market value forecast: $ billion, 2022–27
Table 61: United Kingdom size of population (million), 2018–22
Table 62: United Kingdom gdp (constant 2005 prices, $ billion), 2018–22
Table 63: United Kingdom gdp (current prices, $ billion), 2018–22
Table 64: United Kingdom inflation, 2018–22
Table 65: United Kingdom consumer price index (absolute), 2018–22
Table 66: United Kingdom exchange rate, 2018–22
Table 67: United States pharmaceuticals market value: $ billion, 2017-22
Table 68: United States pharmaceuticals market geography segmentation: $ billion, 2022
Table 69: United States pharmaceuticals market value forecast: $ billion, 2022–27
Table 70: United States size of population (million), 2018–22
Table 71: United States gdp (constant 2005 prices, $ billion), 2018–22
Table 72: United States gdp (current prices, $ billion), 2018–22
Table 73: United States inflation, 2018–22
Table 74: United States consumer price index (absolute), 2018–22
Table 75: United States exchange rate, 2018–22
Table 76: Johnson & Johnson: key facts
Table 77: Johnson & Johnson: Annual Financial Ratios
Table 78: Johnson & Johnson: Key Employees
Table 79: Johnson & Johnson: Key Employees Continued
Table 80: Apotex, Inc.: key facts
Table 81: Apotex, Inc.: Key Employees
Table 82: Laboratoires Pierre Fabre SA: key facts
Table 83: Laboratoires Pierre Fabre SA: Key Employees
Table 84: F. Hoffmann-La Roche Ltd: key facts
Table 85: F. Hoffmann-La Roche Ltd: Annual Financial Ratios
Table 86: F. Hoffmann-La Roche Ltd: Key Employees
Table 87: Boehringer Ingelheim GmbH: key facts
Table 88: Boehringer Ingelheim GmbH: Key Employees
Table 89: A Menarini Industrie Farmaceutiche Riunite Srl: key facts
Table 90: A Menarini Industrie Farmaceutiche Riunite Srl: Key Employees
Table 91: Recordati S.p.A.: key facts
Table 92: Recordati S.p.A.: Annual Financial Ratios
Table 93: Recordati S.p.A.: Key Employees
Table 94: Chiesi Farmaceutici SpA: key facts
Table 95: Chiesi Farmaceutici SpA: Key Employees
Table 96: Daiichi Sankyo Co Ltd: key facts
Table 97: Daiichi Sankyo Co Ltd: Annual Financial Ratios
Table 98: Daiichi Sankyo Co Ltd: Key Employees
Table 99: Daiichi Sankyo Co Ltd: Key Employees Continued
Table 100: Astellas Pharma Inc.: key facts
Table 101: Astellas Pharma Inc.: Annual Financial Ratios
Table 102: Astellas Pharma Inc.: Key Employees
Table 103: Takeda Pharmaceutical Company Limited: key facts
Table 104: Takeda Pharmaceutical Company Limited: Annual Financial Ratios
Table 105: Takeda Pharmaceutical Company Limited: Key Employees
List of Figures
Figure 1: G8 pharmaceuticals industry, revenue($bn), 2018-27
Figure 2: G8 Pharmaceuticals industry, revenue by country (%), 2022
Figure 3: G8 pharmaceuticals industry, revenue by country ($bn), 2018-22
Figure 4: G8 pharmaceuticals industry forecast, revenue by country ($bn), 2022-27
Figure 5: Canada pharmaceuticals market value: $ billion, 2017-22
Figure 6: Canada pharmaceuticals market geography segmentation: % share, by value, 2022
Figure 7: Canada pharmaceuticals market value forecast: $ billion, 2022–27
Figure 8: Forces driving competition in the pharmaceuticals market in Canada, 2022
Figure 9: Drivers of buyer power in the pharmaceuticals market in Canada, 2022
Figure 10: Drivers of supplier power in the pharmaceuticals market in Canada, 2022
Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2022
Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2022
Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2022
Figure 14: France pharmaceuticals market value: $ billion, 2017-22
Figure 15: France pharmaceuticals market geography segmentation: % share, by value, 2022
Figure 16: France pharmaceuticals market value forecast: $ billion, 2022–27
Figure 17: Forces driving competition in the pharmaceuticals market in France, 2022
Figure 18: Drivers of buyer power in the pharmaceuticals market in France, 2022
Figure 19: Drivers of supplier power in the pharmaceuticals market in France, 2022
Figure 20: Factors influencing the likelihood of new entrants in the pharmaceuticals market in France, 2022
Figure 21: Factors influencing the threat of substitutes in the pharmaceuticals market in France, 2022
Figure 22: Drivers of degree of rivalry in the pharmaceuticals market in France, 2022
Figure 23: Germany pharmaceuticals market value: $ billion, 2017-22
Figure 24: Germany pharmaceuticals market geography segmentation: % share, by value, 2022
Figure 25: Germany pharmaceuticals market value forecast: $ billion, 2022–27
Figure 26: Forces driving competition in the pharmaceuticals market in Germany, 2022
Figure 27: Drivers of buyer power in the pharmaceuticals market in Germany, 2022
Figure 28: Drivers of supplier power in the pharmaceuticals market in Germany, 2022
Figure 29: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Germany, 2022
Figure 30: Factors influencing the threat of substitutes in the pharmaceuticals market in Germany, 2022
Figure 31: Drivers of degree of rivalry in the pharmaceuticals market in Germany, 2022
Figure 32: Italy pharmaceuticals market value: $ billion, 2017-22
Figure 33: Italy pharmaceuticals market geography segmentation: % share, by value, 2022
Figure 34: Italy pharmaceuticals market value forecast: $ billion, 2022–27
Figure 35: Forces driving competition in the pharmaceuticals market in Italy, 2022
Figure 36: Drivers of buyer power in the pharmaceuticals market in Italy, 2022
Figure 37: Drivers of supplier power in the pharmaceuticals market in Italy, 2022
Figure 38: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Italy, 2022
Figure 39: Factors influencing the threat of substitutes in the pharmaceuticals market in Italy, 2022
Figure 40: Drivers of degree of rivalry in the pharmaceuticals market in Italy, 2022
Figure 41: Japan pharmaceuticals market value: $ billion, 2017-22
Figure 42: Japan pharmaceuticals market geography segmentation: % share, by value, 2022
Figure 43: Japan pharmaceuticals market value forecast: $ billion, 2022–27
Figure 44: Forces driving competition in the pharmaceuticals market in Japan, 2022
Figure 45: Drivers of buyer power in the pharmaceuticals market in Japan, 2022
Figure 46: Drivers of supplier power in the pharmaceuticals market in Japan, 2022
Figure 47: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Japan, 2022
Figure 48: Factors influencing the threat of substitutes in the pharmaceuticals market in Japan, 2022
Figure 49: Drivers of degree of rivalry in the pharmaceuticals market in Japan, 2022
Figure 50: Russia pharmaceuticals market value: $ billion, 2017-22
Figure 51: Russia pharmaceuticals market geography segmentation: % share, by value, 2022
Figure 52: Russia pharmaceuticals market value forecast: $ billion, 2022–27
Figure 53: Forces driving competition in the pharmaceuticals market in Russia, 2022
Figure 54: Drivers of buyer power in the pharmaceuticals market in Russia, 2022
Figure 55: Drivers of supplier power in the pharmaceuticals market in Russia, 2022
Figure 56: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Russia, 2022
Figure 57: Factors influencing the threat of substitutes in the pharmaceuticals market in Russia, 2022
Figure 58: Drivers of degree of rivalry in the pharmaceuticals market in Russia, 2022
Figure 59: United Kingdom pharmaceuticals market value: $ billion, 2017-22
Figure 60: United Kingdom pharmaceuticals market geography segmentation: % share, by value, 2022
Figure 61: United Kingdom pharmaceuticals market value forecast: $ billion, 2022–27
Figure 62: Forces driving competition in the pharmaceuticals market in the United Kingdom, 2022
Figure 63: Drivers of buyer power in the pharmaceuticals market in the United Kingdom, 2022
Figure 64: Drivers of supplier power in the pharmaceuticals market in the United Kingdom, 2022
Figure 65: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United Kingdom, 2022
Figure 66: Factors influencing the threat of substitutes in the pharmaceuticals market in the United Kingdom, 2022
Figure 67: Drivers of degree of rivalry in the pharmaceuticals market in the United Kingdom, 2022
Figure 68: United States pharmaceuticals market value: $ billion, 2017-22
Figure 69: United States pharmaceuticals market geography segmentation: % share, by value, 2022
Figure 70: United States pharmaceuticals market value forecast: $ billion, 2022–27
Figure 71: Forces driving competition in the pharmaceuticals market in the United States, 2022
Figure 72: Drivers of buyer power in the pharmaceuticals market in the United States, 2022
Figure 73: Drivers of supplier power in the pharmaceuticals market in the United States, 2022
Figure 74: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2022
Figure 75: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2022
Figure 76: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2022

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us